Press Release

Headline / Title /SEO Title:
Veeda Clinical Research & Shimadzu collaborate to explore new avenues in Mass Spectrometry applications for clinical research

Introduction / Sub-head / Meta-description:
Shimadzu (Asia Pacific) Pte Ltd, Singapore, and Veeda Clinical Research Pvt Ltd, India, have signed a Memorandum of Understanding (MoU) to collaborate and develop new analytical methods and improve existing protocols used in BA/BE studies under a regulatory-compliant environment using Mass Spectrometry applications.

Keywords / Tags:
Shimadzu, Veeda, Memorandum of Understanding, MoU, collaborate, BA/BE, Regulatory, Compliance, Mass Spectrometry, Mass Spec, MS,clinical research

Body / Content:
Chennai, India; Aug 22, 2016
Shimadzu (Asia Pacific) Pte Ltd, Singapore, a global leader in analytical instruments and Veeda Clinical Research Pvt Ltd, Ahmedabad, India, one of India's foremost player in the CRO industry, have signed a Memorandum of Understanding (MoU) to collaborate in the areas of clinical research involving mass spectrometers. This state-of-the-art collaboration will see the development of new analytical methods and also lead to improvement in the existing protocols or methods that are used in BA/BE studies under a regulatory-compliant environment. Veeda's laboratories will function as a Partner- Laboratory in India for Shimadzu in this segment. The agreement was signed at Chennai on the occasion of the inauguration of Spinco Towers, Chennai on August 22, 2016.

The partnership heralds a new beginning by enabling studies using 'high sensitivity mass spectrometers' in the field of clinical research, which has seen rapid progress during the last decade. As the need for the ultra-high sensitivity mass spectrometry instruments, to measure drug candidates in various clinical subjects during the trials, is ever-increasing, this collaboration opens up new opportunities to devise unique solutions for solving analytical challenges. This will certainly contribute to an accelerated drug development process.

Mr.Apurva Shah, Group Managing Director, Veeda Clinical Research Pvt Ltd, India, outlined that the cooperation is a significant milestone in Veeda's journey to advance clinical trials to much greater levels of performance. He further said, "Shimadzu's newly launched 'world's highest sensitivity LCMS-8060 triple quadrupole mass spectrometers'are an ideal platform for the ultra-high sensitivity analysis of the drugs and their metabolites in the clinical subjects. The system allows development of superior methods for the detection and quantitation of drugs and their metabolites in complex clinical samples."

Dr.Teruhisa Ueda, President &Chief Executive Officer of Shimadzu Corporation, Japan, who was present during theoccasion, appreciated the world-class infrastructure created at the multiple laboratories of Veeda Clinical Research. DrUeda said that through this agreement,Shimadzu would significantly gain deeper insights in bioanalysis forclinical trials using mass spectrometry.

Mr.KiminobuImura, Managing Director, Shimadzu (Asia Pacific) Pte Ltd, Singapore, who signed the agreement on behalf of Shimadzu, reiterated that his team will extend the maximum support to this initiative both directly and also through their Indian distributor Spinco Biotech, with whom they have had a successful partnership for 33 years.

About Shimadzu (Asia Pacific) Pte Ltd
Shimadzu (Asia Pacific) Pte Ltd is the Asian subsidiary of Shimadzu Corporation, Japan which is a leading technology provider in analytical & life science instrumentation, testing & measurement instruments, medical systems etc. Shimadzu has continued to provide state-of-the-art technology solutions for the past 141 years. The analytical & measuring instruments division has successfully developed new series of highly sensitive mass spectrometers and a host of instruments in chromatography, spectroscopy, life science research that serve in diverse areas of applications such as pharmaceuticals, clinical research, diagnostics, food and beverage, environment, petrochemical, chemical, forensics, energy etc. Through adoption of scientific inventions and cutting-edge technologies, Shimadzu (Asia Pacific) provides its corporate clients with the highest quality in product standards and the delivery of excellent customer support services.

About Veeda Clinical Research Pvt Ltd
Veeda Clinical Research is aleading global player, working on Clinical research and providing world-class services in BA/BE, clinical trials, biosimilars& biologicals, speciality services, pharmaco-vigilance etc. Backed by a vast experience in the field of Clinical Research, Veeda offers speciality services like Central Bioanalytical Services, Biopharmaceutical services, Quality assurance & project management services. Veeda has completed more than 1625+ clinical studies from their Ahmedabad unit and their team was honoured with prestigious awards like Partner of Choice for Phase-1 Studies in 2007 by Frost & Sullivan, Entrepreneur of the Year in 2009 by BioSpectrumand many more. Backed by a strong team of professionals whose values and commitment to innovation and high quality have made Veeda, one of the most trusted CROs in India.

Contact Information

Shimadzu (Asia Pacific) Pte Ltd
Mr Saptarshi Chaudhuri (Bob)
Marketing & Communications
Shimadzu (Asia Pacific) Pte Ltd, Singapore
DID: (+65) 6770 1338
Mob: (+65) 9273 6168
Email: saptarshi@shimadzu.com.sg

Veeda Clinical Research Pvt Ltd
Mr Apurva Shah
Managing Director
Veeda Clinical Research Pvt Ltd, Ahmedabad, India
Tel: (+91) 79 3001 3000
Email: info@veedacr.com